Volume 17, Number 8—August 2011
Dispatch
Neurologic Disorders and Hepatitis E, France, 2010
Table A1
Clinical features and laboratory findings for neurologic disorders associated with hepatitis E infection*
Reference and year | Country | Age, y/sex | Neurologic symptoms | ALT, IU/L | CSF | Other infectious etiologies excluded by serologic or molecular testing | Serum | CSF | Treatment/outcome | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Leukocytes, cells/mm3 | Protein, g/L | Anti-HEV IgM | Anti-HEV IgG | HEV RNA | Anti-HEV IgM | Anti-HEV IgG | HEV RNA | ||||||||||
Cases from this study | |||||||||||||||||
Case 1, 2010 | France | 54/F | Meningitis with neuralgic pain: headaches, photophobia, diffuse paresthesia, and pain of upper and lower limbs | 566 | 74 | 1.03 | Serum: HAV, HBV, HCV, HIV, measles virus, rubella virus, HSV, VZV, EBV, parvovirus B19, dengue virus, Leptospira spp., Brucella spp., Coxiella burnetii, Rickettsia conorii, R. typhi, R. felis | + | + | + Genotype 3 | + | NT | + Genotype 3 | Total recovery in 2 wk | |||
CSF: CMV, HSV, VZV, EBV, HHV6, Toscana virus, mumps virus, measles virus, Listeria monocytogenes, Mycobacteria spp., Mycoplasma spp., all bacteria (16S ribosomal RNA detection) | |||||||||||||||||
Case 2, 2010 | France | 49/M | Polyradiculoneuropathy: Proximal muscle weakness, paresthesia, and pain of upper and lower limbs | 78 | 10 | 1.02 | Serum: HAV, HBV, HCV, HIV, EBV, CMV, VZV, parvovirus B19, mumps virus, brucellosis, Bartonella henselae, Bartonella quintana | + | + | + Genotype 3 | – | NT | – | Clinical recovery in 2 wk | |||
CSF: EBV, HSV, VZV, enterovirus, Toscana virus, WNV, Borrelia burgdorferi, all bacteria (16S ribosomal RNA detection) | |||||||||||||||||
Cases reported in the literature | |||||||||||||||||
Guillain-Barré syndrome: | |||||||||||||||||
(6), 2000 | India | 50/M | Generalized paresthesia, weakness of the lower limbs, hypotonia, areflexia | 114 | <5 | 1.86 | Serum: HAV, HBV, HCV | + | NT | NT | NT | NT | NT | Improvement 2 wk after neurologic onset; total recovery within 1 mo | |||
(7), 2002 | India | 35/M | Weakness of upper and lower limbs and of respiratory muscles | 752 | NT | NT | Serum: HAV, HBV, HCV, HDV, HIV | + | NT | NT | NT | NT | NT | IVIG; total recovery within 2 wk | |||
(8), 2005 | India | 58/F | Muscular weakness, diffuse areflexia, left infranuclear facial palsy | 1,448 | <2 | 0.80 | Serum: HAV, HBV, HCV | + | NT | NT | NT | NT | NT | IVIG, plasmapheresis; total neurologic recovery in 2 wk; tiver biochemistry normalized after about 5 wk | |||
(3), 2008 | United Kingdom | 42/M | Paresthesia and weakness in lower limbs | 632 | NA | NA | NA | + | NA | + Genotype 3 | NT | NT | – | Total recovery after 3 mo | |||
(9), 2009 | Belgium | 66/M | Progressive ataxia; weakness and paresthesia of legs, with ataxia and neuropathic pain | 1,813 | <5 | 1.72 | Serum: HAV, HBV, HCV, HIV, VZV, CMV, EBV, HSV, adenovirus, Campylobacter spp. | + | NT | NT | NT | NT | NT | IVIG; progressive improvement of walking perimeter and pain within 4 mo | |||
(10), 2010 | Czech Republic | 65/M | Loss of strength in upper limbs and partially in lower limbs; pain in both shoulders | 1,920 | 7 | 0.7 | Serum: HSV, EBV, CMV, HAV, HBV, HCV, enterovirus, inflluenza A/B virus, parainfluenza viruses 1–3, adenovirus, tick-borne encephalitis virus, Borrelia burgdorferi, Anaplasma phagocytophilum, Chlamydia pneumoniae, Mycoplasma spp. | + | +† | NT | NT | NT | NT | Persistence of residual tetraparesis 19 mo after onset (chronic demyelinating polyneuropathy); improvement after IVIG | |||
CSF: VZV,HSV, enterovirus, A. phagocytophilum, C. pneumoniae, Mycoplasma spp. B. burgdorferi. | |||||||||||||||||
(11), 2010 | Ireland | 40/M | Progressive weakness of the legs; paresthesia of hands and feet, then quadriplegia, repiratory insufficiency, and facial weakness | 57 | <5 | 0.38 | Serum: HAV, HBV, HCV, HIV, CMV, EBV | +‡ | NA | NT | NT | NT | NT | IVIG, followed by plasmapheresis; total recovery within 6 mo | |||
(4), 2010 | France | 44/M | Peripheral nerve involvement; proximal muscular weakness of the joints of the 4 limbs; bilateral pyramidal syndrome | 105 | 7 | 0.76 | Serum: HBV, HCV, HIV, CMV, EBV | + | + | + Genotype 3 | – | – | + Genotype 3 | IVIG; no improvement; death 1 mo later from decompensated cirrhosis | |||
CSF: CMV, HSV, VZV, JC virus, Cryptococcus antigen, Toxoplasma gondii, Candida spp | |||||||||||||||||
Other neurologic diagnosis | |||||||||||||||||
(1), 2001 | India | 28/F | Meningoencephalitis: nuchal rigidity; drowsiness; desorientation; bilateral Babinski reflex and seizure | 1,890 | 12 | 1.10 | Serum: HAV, HBV, HCV, HIV, EBV, Treponema pallidum | + | + at mo 6 | NT | NT | NT | NT | Improvement of neurologic symptoms in 3 wk | |||
(12), 2006 | India | 12/F | Acute transverse myelitis: weakness of lower limbs with sphincter dysfunction, pyramidal syndrome | NA | NA | NA | Serum: HAV, HBV, HCV, measles virus, rubella virus, HSV | + | NA | NT | NT | NT | NT | Total recovery within 10 d without treatment | |||
(2), 2006 | India | 32/M | Bell palsy: right-sided lower motor neuron facial palsy | 1,000 | NA | NA | Serum: HAV, HBV, HIV, T. pallidum | + | NT | NT | NT | NT | NT | Total recovery in 3 wk | |||
(13), 2009 | United Kingdom | 44/M | Bilateral neuralgic amyotrophy of upper limbs | 2,547 | NT | NT | Serum: HAV, HBV, HCV, Borrelia burgdorferi, Treponema pallidum, HTLV | + | NT | NT | NT | NT | NT | Resolution of pain 6 wk after onset; total recovery of sensory motor deficiency in 2 y |
*ALT, alanine aminotransferase level; CSF, cerebrospinal fluid; HEV, hepatitis E virus; Ig, immunoglobulin; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HSV, herpes simplex virus; VZV, varicella zoster virus; EBV, Epstein-Barr virus; +, positive; NT, not tested; CMV, cytomegalovirus; HHV6, human herpes virus 6; –, negative; HDV, hepatitis D virus, WNV, West Nile virus; HDV, hepatitis D virus; IVIG, intravenous immunoglobulin; NA, not available; HTLV, human T-lymphotropic virus.
†Two weeks after first anti-HEV IgM detection.
‡Weakly positive.
References
- Colson P, Borentain P, Queyriaux B, Kaba M, Moal V, Gallian P, Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis. 2010;202:825–34. DOIPubMedGoogle Scholar
- Zhai L, Dai X, Meng J. Hepatitis E virus genotyping based on full-length genome and partial genomic regions. Virus Res. 2006;120:57–69. DOIPubMedGoogle Scholar
- Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis. 2010;51:525–30. DOIPubMedGoogle Scholar